Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of different doses of Creon
Immediate Release (IR) in comparison to Creon® 25,000 Delayed Release/Gastro-Resistant
(DR/GR) in subjects with Pancreatic Exocrine Insufficiency (PEI) due to Cystis Fibrosis (CF).